Prophylaxis for Pneumocystis Pneumonia (PCP) in non-HIV infected patients
More details
Hide details
Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece
Demosthenes Bouros   

Dept of Pneumonology, Medical School, Democritus University of Thrace, Greece Alexandroupolis 68100
Pneumon 2012;25(4):348–350
Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 1975; 112:47-50.
Jacobs JL, Libby DM, Winters RA, et al. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N Engl J Med. 1991;324(4):246-50.
Cano S, Capote F, Pereira A, et al. Pneumocystis carinii pneumonia in patients without predisposing illnesses. Acute episode and follow-up of five cases. Chest 1993; 104:376-81.
Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82:1052-9.
Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med 1995; 151:795-9.
Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 2008; 59:1034-9.
Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267:832-7.
Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005; 128:573-9.
Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings, June 2007. http://www.cdc.gov/
Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49:1-125.
Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.
Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122-74.
Stiehm, ER, Ochs, HD, Winkelstein, JA. Immunodeficiency disorders: General considerations. In: Immunological Disorders in Infants and Children, 5th ed, Stiehm, ER, Ochs, HD, Winkelstein, JA (Ed), Elsevier Saunders, Philadephia 2004. p.289.
Ochs HD, Stiehm ER, Winkelstein JA. Antibody deficiencies. In: Immunological Disorders in Infants and Children, 5th ed, Stiehm, ER, Ochs, HD, Winkelstein, JA (Ed), Elsevier Saunders, Philadelphia 2004. p.357.
Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/ dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23:1186-8.
White ES, Lynch JP. Pharmacological therapy for Wegener’s granulomatosis. Drugs 2006; 66:1209-28.
Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666-73.
Thomas C, Limper A. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98.
Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5:84-93.
Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770-82.
Thomas CF, Limper AH. Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients. Uptodate, Wolters Kluwer Health, 2012.
Pope J, Jerome D, Fenlon D, Krizova A, Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:480-4.
Jeffries M, Bruner G, Glenn S, et al. Sulpha allergy in lupus patients: a clinical perspective. Lupus. 2008;17:202-5.